Vector Science and Therapeutics Corp. ("Vector" or the "Company") is pleased to announce that the Company has entered into an investor relations agreement (the "IR Agreement") with RedChip Companies, Inc. ("RedChip") through its principal, Dave Gentry, dated August 24, 2026.

The IR Agreement has a twelve-month term and may be renewed or otherwise amended and agreed to in writing by the parties. The Company has agreed to pay RedChip US$8,500, in advance on a monthly basis, for services to be provided commencing on the effective date of the agreement. Under the terms of the IR Agreement, RedChip has agreed to assist the Company with certain investor relations related activities, including communicating with investment advisors, analysts, portfolio managers, and media contacts together with perfecting investor collateral, including investor decks, website disclosure in preparation for outreach to institutions, analysts and media outlets (collectively, the "IR Services"), all in accordance with the policies of the TSX Venture Exchange ("TSXV") and applicable securities laws.

Pursuant to the IR Agreement, the Company has granted RedChip stock options ("IR Options") to purchase up to 150,000 common shares of the Company at a price of C$1.80 per share. The IR Options expire on August 24, 2029, vesting from the grant date on a quarterly basis over the term of the IR Agreement. The IR Options are subject to the approval of the TSXV.

RedChip is a United States investor relations firm based in Maitland, FL. RedChip is owned by its CEO, Dave Gentry, and has no direct relationship with and is arms-length from the Company, other than as disclosed in this news release. Neither RedChip nor any of its principals currently hold common shares of the Company. RedChip has been granted Options to purchase up to 150,000 common shares of the Company pursuant to the terms of the IR Agreement described above. The IR Agreement and the engagement of RedChip pursuant thereto remain subject to the approval of the TSXV.